ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. diff . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations ...

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

...ts drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, includi...surance that we will conduct additional studies with for acute treatment of hae or that we will be successful in gaining regulatory approval of Cinryze for...

ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor re...

Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release: August 3, 2009

... BRAINTREE, Mass., July 13 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: hae ) will announce its Q1FY10 earnings on August 3, 2009 in a pre-market press release and 10:00 am (EDT) webcast. Webcast Link: http://phx.c...

Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies

... approximately 10,000 people in the United States. hae causes recurrent attacks of intense localized edem...ens or plasmin inhibitors has been the mainstay of hae therapy, many new therapies for prophylaxis and ac...he signs and symptoms of patients who present with hae and to be familiar with the conventional and emerg...

Changing Paradigms in Hereditary Angioedema: Pathophysiology, Diagnosis and Treatment

...ween 4,000 and 10,000 people in the United States. hae causes recurrent attacks of intense localized edem...ens or plasmin inhibitors has been the mainstay of hae therapy, many new therapies for prophylaxis and ac...sicians to understand the diagnostic strategies in hae as well as the conventional and emerging therapeut...

Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results

...uartered in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol hae on the TSX. Forward-looking Statements Certain of the statements contained in this news release are forward-looking statements. Such stateme...

ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

ViroPharma to Present at Two May Healthcare Conferences

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

More>>

Hae in Medical Technology

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...Workshop presentations focusing on items including hae treatment considerations and the potential for sub... develop therapy considerations for prophylaxis of hae in the U.S.; The abstract suggested that patients with frequent hae attacks, severe attacks, past laryngeal attacks, e...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies

...ated to afflict 10,000 people in the United States each year. Patients with hae suffer from recurrent attacks of intense localized edema involving the skin...ts. The faculty for these lectures comprises experts in immunology and hae from leading medical institutions. The chairperson is Bruce L. Zuraw, MD, P...

ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients

... http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

... - PDUFA Date for Cinryze for Acute hae Indication is June 3, 2009 - EXTON, Pa., Feb...ryze produced beneficial effects in treating acute hae attacks in these studies. The safety profile was s...y and efficacy profile of Cinryze for treatment of hae attacks. The primary efficacy measure in the pivo...

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema

... and New Data Suggesting Need for Improved hae Screening Presented at ACAAI 2008 Annual Meeting -...e of analysis. Patients suffering acute attacks of hae who were treated with Cinryze experienced improvem...nofiltered C1-inhibitor for the treatment of acute hae attacks." Eighty-eight (88) subjects with document...

ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals

...tly reduce the severity, duration and frequency of hae attacks. Separately, ViroPharma announced that t...ient access program and launching Cinryze into the hae prophylaxis market," commented Vincent Milano, Vir...ial, Cinryze significantly decreased the number of hae attacks compared to placebo. The trial had a cross...

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

...AZYR (Icatibant), a peptide based therapeutic for hae which has received a positive opinion from the Co...designation in the EU and US: approximately 10,000 hae diagnosed patients; estimated prevalence is one in 50,000 individuals - First-in-class hae therapy that provides rapid access in a convenient...

CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema

...tive treatment for acute hae attacks KING OF PRUSSIA, Pa., March 6 /PRNewswir...ema C1-Inhibitor Trial (I.M.P.A.C.T.), the largest hae trial ever, that studied the efficacy of pasteuriz..., there are no specifically-approved therapies for hae in North America. "Submission of the BLA for C1-...

CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema

...eduction in time to onset of relief of symptoms of hae attacks compared to placebo (p= 0.003, one sided)....n immediately impact the lives of the thousands of hae patients around the world who live with the burden of acute hae attacks without approved treatment," said Timothy ...

More>>

Hae in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

...ly driven by increased volumes in Europe and Asia Pacific. FIRAZYR - hae Sales for the three months to June 30, 2009 were $1.5 million (2008:...will enable launch in Italy during Q3. FIRAZYR is the first new product for hae in Europe in 30 years and has orphan exclusivity in the EU until 2018. ...

Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology

...E, Mass., June 4 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: hae ) announced today that the U.S. District Court for the District of Massachu...upport customers through this transition period." Haemonetics (NYSE: hae ) is a global healthcare company dedicated to providing innovative blood ma...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

...ryze is already successfully preventing attacks of hae in many patients, there remains an unmet medical n...events. "Patients in the United States with hae have been waiting for a safe and effective emergen... routine prophylaxis against angioedema attacks in hae patients. Cinryze is administered at an injection ...

ViroPharma to Present at Two June Healthcare Conferences

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

...ting disorder -- hereditary angioedema (HAE). hae is a rare, severely debilitating, life-threatening...ere are estimated to be at least 4,600 people with hae in the United States. "We are honored to be r...gnized by NORD for our work in bringing Cinryze to hae patients in the U.S.," said Vincent Milano, ViroPh...

Shire begins the year with a strong performance

...imarily driven by increased unit sales in Europe and Asia. FIRAZYR - hae Sales for the three months to March 31, 2009 were $0.5 million (2008...s and patients has been very positive. FIRAZYR is the first new product for hae in Europe in 30 years and has orphan exclusivity in the EU until 2018. ...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... CINRYZE Solutions (TM) and improving the level of hae awareness among treating physicians. We remain wel...ities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely pos...ding the pivotal Phase 3 study of Cinryze in acute hae attacks and the ongoing open-label study of Cinryz...

ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009

...http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile . ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...

Publication of Shire plc's Annual Report 2008

... in the US FIRAZYR is a treatment for acute hae which Shire added to the portfolio through its acq... acquired more than 98% of Jerini, adding Jerini's hae product, FIRAZYR, to the portfolio; and ...n Jerini. The acquisition has added Jerini's hae product, FIRAZYR, to the portfolio. - In Nove...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

... http://www.viropharma.com/Products.aspx ). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), hae and C. difficile. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relati...